Amgen (AMGN)
(Real Time Quote from BATS)
$333.42 USD
+8.33 (2.56%)
Updated Jul 12, 2024 02:30 PM ET
3-Hold of 5 3
C Value D Growth B Momentum D VGM
Price, Consensus and EPS Surprise
AMGN 333.42 +8.33(2.56%)
Will AMGN be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for AMGN based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for AMGN
Pfizer (PFE) Moves Forward With Once-Daily Obesity Pill Study
Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It
AMGN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Novo Nordisk (NVO) Soars 38% YTD: How Should You Play the Stock?
AbbVie (ABBV) Up 24% in a Year: Buy, Sell or Hold the Stock?
Study Shows Lilly's (LLY) Obesity Drug More Effective Than NVO's
Other News for AMGN
Eliem Therapeutics: Year End 2024 MN Data With Further Potential To Unlock Value
10 Blue-Chip Dividend Growth Stocks With 3% Yields And Safe Dividends
Amgen price target raised by $40 at Argus, here's why
Smart Money Is Betting Big In AMGN Options
From Sci-Fi Dream to Market Maze: Eli Lilly's Weight-Loss Medication Faces Hurdles